Literature DB >> 30018117

Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?

Christopher C Coss1,2, Steven K Clinton2,3, Mitch A Phelps4,2.   

Abstract

Immune checkpoint inhibition is dramatically improving patient outcomes in diverse cancers, many of which responded poorly to traditional cytotoxic agents. Drivers of heterogeneous response to immune checkpoint therapy are poorly characterized. Cachectic cancer patients exhibit elevated pembrolizumab clearance and poor response, highlighting the immense therapeutic challenge posed by cancer cachexia.See related article by Turner et al., p. 5841. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30018117      PMCID： PMC6279566          DOI： 10.1158/1078-0432.CCR-18-1847

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.

Authors:  Thomas A Mace; Reena Shakya; Jason R Pitarresi; Benjamin Swanson; Christopher W McQuinn; Shannon Loftus; Emily Nordquist; Zobeida Cruz-Monserrate; Lianbo Yu; Gregory Young; Xiaoling Zhong; Teresa A Zimmers; Michael C Ostrowski; Thomas Ludwig; Mark Bloomston; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Gut       Date:  2016-10-21       Impact factor: 23.059

Review 2.  Connecting the Metabolic and Immune Responses to Cancer.

Authors:  Thomas R Flint; Douglas T Fearon; Tobias Janowitz
Journal:  Trends Mol Med       Date:  2017-04-07       Impact factor: 11.951

3.  Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.

Authors:  David C Turner; Anna G Kondic; Keaven M Anderson; Andrew G Robinson; Edward B Garon; Jonathan Wesley Riess; Lokesh Jain; Kapil Mayawala; Jiannan Kang; Scot W Ebbinghaus; Vikram Sinha; Dinesh P de Alwis; Julie A Stone
Journal:  Clin Cancer Res       Date:  2018-06-11       Impact factor: 12.531

Review 4.  Cancer-associated cachexia.

Authors:  Vickie E Baracos; Lisa Martin; Murray Korc; Denis C Guttridge; Kenneth C H Fearon
Journal:  Nat Rev Dis Primers       Date:  2018-01-18       Impact factor: 52.329

Review 5.  Pharmacokinetics of Monoclonal Antibodies.

Authors:  Josiah T Ryman; Bernd Meibohm
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-29
  5 in total
  15 in total

Review 1.  Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.

Authors:  Vishal Navani; Moira C Graves; Nikola A Bowden; Andre Van Der Westhuizen
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

2.  Melanoma: An immunotherapy journey from bench to bedside.

Authors:  Vishal Navani; Moira C Graves; Hiren Mandaliya; Martin Hong; Andre van der Westhuizen; Jennifer Martin; Nikola A Bowden
Journal:  Cancer Treat Res       Date:  2022

Review 3.  The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer.

Authors:  Rishi Jain; Chris Coss; Peter Whooley; Mitch Phelps; Dwight H Owen
Journal:  Curr Oncol Rep       Date:  2020-05-15       Impact factor: 5.075

Review 4.  Cachexia Anorexia Syndrome and Associated Metabolic Dysfunction in Peritoneal Metastasis.

Authors:  Rami Archid; Wiebke Solass; Clemens Tempfer; Alfred Königsrainer; Michael Adolph; Marc A Reymond; Robert B Wilson
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

5.  Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer.

Authors:  Chung-Shien Lee; Craig E Devoe; Xinhua Zhu; Joanna Stein Fishbein; Nagashree Seetharamu
Journal:  Lung Cancer Manag       Date:  2020-04-24

Review 6.  ER Stress and Unfolded Protein Response in Cancer Cachexia.

Authors:  Anirban Roy; Ashok Kumar
Journal:  Cancers (Basel)       Date:  2019-12-03       Impact factor: 6.639

7.  Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.

Authors:  Brendan D Curti; Yoshinobu Koguchi; Rom S Leidner; Annah S Rolig; Elizabeth R Sturgill; Zhaoyu Sun; Yaping Wu; Venkatesh Rajamanickam; Brady Bernard; Ian Hilgart-Martiszus; Christopher B Fountain; George Morris; Noriko Iwamoto; Takashi Shimada; ShuChing Chang; Peter G Traber; Eliezer Zomer; J Rex Horton; Harold Shlevin; William L Redmond
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

8.  Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans.

Authors:  Alyssa Marie M Castillo; Trang T Vu; Sophia G Liva; Min Chen; Zhiliang Xie; Justin Thomas; Bryan Remaily; Yizhen Guo; Uma L Subrayan; Travis Costa; Timothy H Helms; Donald J Irby; Kyeongmin Kim; Dwight H Owen; Samuel K Kulp; Thomas A Mace; Mitch A Phelps; Christopher C Coss
Journal:  JCSM Rapid Commun       Date:  2021-02-09

9.  C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.

Authors:  Go Noguchi; Noboru Nakaigawa; Susumu Umemoto; Kota Kobayashi; Yosuke Shibata; Sohgo Tsutsumi; Masato Yasui; Shinji Ohtake; Takahisa Suzuki; Kimito Osaka; Kentaro Muraoka; Hisashi Hasumi; Keiichi Kondo; Yuka Igarashi; Tetsuro Sasada; Takeshi Kishida; Masahiro Yao
Journal:  Cancer Chemother Pharmacol       Date:  2020-06-14       Impact factor: 3.333

10.  Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers.

Authors:  Vishal Navani; Moira C Graves; Giovana Celli Marchett; Hiren Mandaliya; Nikola A Bowden; Andre van der Westhuizen
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.